The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells

Photochemistry and Photobiology

Volumn 86, Issue 5, 2010, Pages 1154-1160

  Blake, Emma ^a   Curnow, Alison ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIETHYL 3 HYDROXYPYRIDIN 4 ONE; 1,2-DIETHYL-3-HYDROXYPYRIDIN-4-ONE; IRON CHELATING AGENT; PROTOPORPHYRIN; PYRIDONE DERIVATIVE;

ARTICLE; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; GLIOMA; HUMAN; METABOLISM; PHOTOCHEMOTHERAPY; RADIATION EXPOSURE;

CELL SURVIVAL; CELLS, CULTURED; GLIOMA; HUMANS; IRON CHELATING AGENTS; PHOTOCHEMOTHERAPY; PROTOPORPHYRINS; PYRIDONES;

EID: 77956478557     PISSN: 00318655     EISSN: 17511097     Source Type: Journal    
DOI: 10.1111/j.1751-1097.2010.00770.x     Document Type: Article

References (33)

1. Muller, P. J. B. C. Wilson (2006) Photodynamic therapy of brain tumors - A work in progress. Lasers Surg. Med. 38, 384 389.
2. Madsen, S. J., C. H. Sun, B. J. Tromberg, V. P. Wallace H. Hirschberg (2000) Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid. Photochem. Photobiol. 72, 128 134.
3. Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu M. J. Thun (2007) Cancer statistics, 2007. CA Cancer J. Clin. 57, 43 66.
4. Pass, H. I. (1993) Photodynamic therapy in oncology: Mechanisms and clinical use. J. Natl Cancer Inst. 85, 443 456.
5. Kaneko, S. (2008) Recent advances in PDD and PDT for malignant brain tumours. Rev. Laser Eng. 36, 1351 1354.
6. Stummer, W., S. Stocker, S. Wagner, H. Stepp, C. Fritsch, C. Goetz, A. E. Goetz, R. Kiefmann H. J. Reulen (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42, 518 525.
7. Liu, H. F., S. Z. Xu C. R. Zhang (2004) Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy. Chin Med J (Engl) 117, 922 926.
8. Szeimies, R. M., P. Calzavara-Pinton, S. Karrer, B. Ortel M. Landthaler (1996) Topical photodynamic therapy in dermatology. J. Photochem. Photobiol. B, Biol. 36, 213 219.
9. Pye, A. A. Curnow (2007) Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochem. Photobiol. 83, 766 773.
10. Hanania, J. Z. Malik (1992) The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. Cancer Lett. 65, 127 131.
11. Berg, K., H. Anholt, O. Bech J. Moan (1996) The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br. J. Cancer 74, 688 697.
12. Tudge, S. H., A. H. Kaye J. S. Hill (1999) Modulation of light delivery in photodynamic therapy of brain tumours. J. Clin. Neurosci. 6, 227 232.
13. Muller, P. J. B. C. Wilson (1996) Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. J. Clin. Laser Med. Surg. 14, 263 270.
14. Stylli, S. S., A. H. Kaye, L. MacGregor, M. Howes P. Rajendra (2005) Photodynamic therapy of high grade glioma - Long term survival. J. Clin. Neurosci. 12, 389 398.
15. Wu, S. M., Q. G. Ren, M. O. Zhou, Q. Peng J. Y. Chen (2003) Protoporphyrin IX production and its photodynamic effects on glioma cells, neuroblastoma cells and normal cerebellar granule cells in vitro with 5-aminolevulinic acid and its hexylester. Cancer Lett. 200, 123 131.
16. Agency, E. M. (2007) European Public Assessment Report EPAR Gliolan. European Medicines Agency (EMA), London, UK.
17. Eljamel, M. S., C. Goodman H. Moseley (2008) ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: A single centre Phase III randomised controlled trial. Lasers Med. Sci. 23, 361 367.
18. Friesen, S. A., G. O. Hjortland, S. J. Madsen, H. Hirschberg, O. Engebraten, J. M. Nesland Q. Peng (2002) 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). Int. J. Oncol. 21, 577 582.
19. Henderson, B. W., T. M. Busch J. W. Snyder (2006) Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med. 38, 489 493.
20. Robinson, D. J., H. S. de Bruijn, N. van der Veen, M. R. Stringer, S. B. Brown W. M. Star (1999) Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin. Photochem. Photobiol. 69, 61 70.
21. Curnow, A., B. W. McIlroy, M. J. Postle-Hacon, A. J. MacRobert S. G. Bown (1999) Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem. Photobiol. 69, 71 76.
22. Al-Waili, N. S., G. J. Butler, J. Beale, R. W. Hamilton, B. Y. Lee P. Lucas (2005) Hyperbaric oxygen and malignancies: A potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med. Sci. Monit. 11, RA279 RA289.
23. Curnow, A., B. W. McIlroy, M. J. Postle-Hacon, J. B. Porter, A. J. MacRobert S. G. Bown (1998) Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br. J. Cancer 78, 1278 1282.
24. Hirschberg, H., C. H. Sun, B. J. Tromberg S. J. Madsen (2002) ALA- and ALA-ester-mediated photodynamic therapy of human glioma spheroids. J. Neurooncol. 57, 1 7.
25. Lilge, L. B. C. Wilson (1998) Photodynamic therapy of intracranial tissues: A preclinical comparative study of four different photosensitizers. J. Clin. Laser Med. Surg. 16, 81 91.
26. Perotti, C., A. Casas, H. Fukuda, P. Sacca A. Batlle (2002) ALA and ALA hexyl ester induction of porphyrins after their systemic administration to tumour bearing mice. Br. J. Cancer 87, 790 795.
27. Rodriguez, L., A. Batlle, G. Di Venosa, S. Battah, P. Dobbin, A. J. Macrobert A. Casas (2006) Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells. Br. J. Pharmacol. 147, 825 833.
28. Ennis, S. R., A. Novotny, J. Xiang, P. Shakui, T. Masada, W. Stummer, D. E. Smith R. F. Keep (2003) Transport of 5-aminolevulinic acid between blood and brain. Brain Res. 959, 226 234.
29. Fredenburg, A. M., R. K. Sethi, D. D. Allen R. A. Yokel (1996) The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4- one in the rat. Toxicology 108, 191 199.
30. Porter, J. B., R. D. Abeysinghe, K. P. Hoyes, C. Barra, E. R. Huehns, P. N. Brooks, M. P. Blackwell, M. Araneta, G. Brittenham, S. Singh, P. Bobbin R. C. Hider (1993) Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site. Br. J. Haematol. 85, 159 168.
31. Brittenham, G. M. (1992) Development of iron-chelating agents for clinical use. Blood 80, 569 574.
32. Campbell, S. M., C. A. Morton, R. Alyahya, S. Horton, A. Pye A. Curnow (2008) Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br. J. Dermatol. 159, 387 393.
33. Pye, A., S. Campbell A. Curnow (2008) Enhancement of methyl- aminolevulinate photodynamic therapy by iron chelation with CP94: An in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. J. Cancer Res. Clin. Oncol. 134, 841 849.